Restructuring Charges

12 Months Ended

Sep. 28, 2019

Restructuring and Related Activities [Abstract]

The Company evaluates its operations for opportunities to improve operational effectiveness and efficiency, including facility and operations consolidation, and to better align expenses with revenues. As a result of these assessments, the Company has undertaken various restructuring actions which are described below. The following table displays charges taken related to restructuring actions in fiscal 2019, 2018 and 2017 and a rollforward of the charges to the accrued balances as of September 28, 2019:



	Fiscal 2019 Actions		Fiscal 2018 Actions			Fiscal 2017 Actions		Other		Total
Restructuring Charges
Fiscal 2017 charges:
Workforce reductions	$	—	$	—		$	8.5	$	—	$	8.5
Facility closure costs	—		—			—		4.8		4.8
Fiscal 2017 restructuring charges	$	—	$	—		$	8.5	$	4.8	$	13.3
Fiscal 2018 charges:
Workforce reductions	$	—	$	11.7		$	—	$	—	$	11.7
Facility closure costs	—		0.9			—		1.6		2.5
Fiscal 2018 restructuring charges	$	—	$	12.6		$	—	$	1.6	$	14.2
Fiscal 2019 charges:
Workforce reductions	$	4.0	$	1.4		$	—	$	—	$	5.4
Facility closure costs	—		(0.2		)	—		1.4		1.2
Fiscal 2019 restructuring charges	$	4.0	$	1.2		$	—	$	1.4	$	6.6



	Fiscal 2019 Actions			Fiscal 2018 Actions			Fiscal 2017 Actions			Previous Other Charges			Total
Rollforward of Accrued Restructuring
Balance as of September 24, 2016	$	—		$	—		$	—		$	6.3		$	6.3

Fiscal 2017 restructuring charges	$	—		$	—		$	8.5		$	4.8		$	13.3
Severance payments	—			—			(1.0		)	(5.6		)	(6.6		)
Other payments	—			—			—			(1.5		)	(1.5		)
Balance as of September 30, 2017	$	—		$	—		$	7.5		$	4.0		$	11.5

Fiscal 2018 restructuring charges	$	—		$	12.6		$	—		$	1.6		$	14.2
Stock-based compensation	—			(1.3		)	—			—			(1.3		)
Severance payments and adjustments	—			(6.8		)	(6.7		)	(0.2		)	(13.7		)
Other payments	—			(0.2		)	—			(1.4		)	(1.6		)
Balance as of September 29, 2018	$	—		$	4.3		$	0.8		$	4.0		$	9.1

Fiscal 2019 restructuring charges	$	4.0		$	1.2		$	—		$	1.4		$	6.6
Severance payments and adjustments	(3.0		)	(3.9		)	(0.8		)	—			(7.7		)
Other payments	—			(0.5		)	—			(1.6		)	(2.1		)
Balance as of September 29, 2018	$	1.0		$	1.1		$	—		$	3.8		$	5.9

Fiscal 2019 Actions

During fiscal 2019, the Company decided to transfer certain shared services positions to its Costa Rica facility from its Marlborough location and announced the termination of 24 personnel and implemented other employee termination actions. The charges for these actions are being recorded pursuant to ASC 420, Exit or Disposal Cost Obligations (ASC 420) for one-time termination benefits. The Company recorded severance benefits charges of $4.0 million in the fiscal 2019 related to these actions. The Company expects to finalize the transition to Costa Rica in the first quarter of fiscal 2020 and record an additional charge of $0.1 million as a result of the service requirement during the transition period.

Fiscal 2018 Actions

During the first, second and third quarters of fiscal 2018, the Company decided to terminate certain employees across the organization, including a corporate executive and primarily sales and marketing personnel in its Diagnostics and Medical Aesthetics reportable segments. The charges were recorded pursuant to ASC 712, Compensation-Nonretirement Postemployment Benefits (ASC 712) or ASC 420 depending on the employee. As such, the Company recorded severance benefits charges of $9.0 million in fiscal 2018. Included within the charge is $1.3 million related to the modification of equity awards.

During fiscal 2018, the Company finalized its decision and plan to consolidate its legacy international accounting and customer service organizations into its Manchester, UK location and will be eliminating these positions in Belgium, France, Italy, Spain and Germany. This transition was completed in the first quarter of fiscal 2019 and these employees were terminated. During fiscal 2018, the Company recorded $2.2 million for severance benefits pursuant to both ASC 712 and ASC 420 depending on the legal requirements on a country by country basis. The Company recorded an additional $1.0 million in fiscal 2019 for the remaining pro-rata charges. This plan is completed.

During the third quarter of fiscal 2018, the Company decided to close its Hicksville, New York facility where it manufactured certain Cynosure products. In connection with this plan, certain employees, primarily in manufacturing, were terminated. The employees were notified of termination and related benefits in the third quarter of fiscal 2018, and the Company recorded these charges pursuant to ASC 420. Employees were required to remain employed during this transition period and charges were recorded ratably over the required service period. The Company recorded a total of $0.5 million in severance benefits charges in fiscal 2018. The Company recorded an additional $0.3 million in the first quarter of fiscal 2019 for the remaining pro-rata charges. This plan is completed.

In the third quarter of fiscal 2018, the Company determined it would not use warehouse space located on Lyberty Way in Westford, Massachusetts. The Company met the cease use date criteria in the third quarter of fiscal 2018 and estimated the time period to sublet the space and related sublease rates resulting in a lease obligation charge of $0.9 million. During the first quarter of fiscal 2019, the Company executed a termination agreement with the landlord and agreed to pay a termination payment of $0.6 million resulting in a benefit of $0.2 million recorded in the first quarter of fiscal 2019.

Fiscal 2017 Actions

During the second quarter of fiscal 2017, the Company completed its acquisition of Cynosure. In connection with the acquisition, the Company decided to terminate certain Cynosure executives in the second quarter of fiscal 2017 and recorded $1.5 million in severance benefits charges. During the third and fourth quarters of fiscal 2017, the Company terminated additional executives and employees and recorded $4.3 million and $1.3 million, respectively, in severance benefits charges. The charges were recorded pursuant to ASC 712 and ASC 420 depending on the executive.

During the fourth quarter of fiscal 2017, the decision was made to reduce headcount and related costs in R&D within Breast Health and to eliminate certain manufacturing personnel, primarily in Diagnostics. The majority of employees were notified of termination and related benefits in the fourth quarter of fiscal 2017, and the Company recorded these charges pursuant to ASC 420 as the benefits qualify as one-time termination benefits. As such, the Company recorded severance benefits charges of $1.4 million in the fourth quarter.

Other

In connection with the closure of the Bedford location during the first quarter of fiscal 2017, the Company recorded $3.5 million for lease obligation charges related to the first floor of the facility as the Company determined it had met the cease-use date criteria. The Company made certain assumptions regarding the time period it would take to obtain a subtenant and the sublease rates it could obtain. During the third quarter of fiscal 2017, the Company updated its assumption regarding the time period it would take to obtain a subtenant at the Bedford location and as a result recorded an additional $1.3 million lease obligation charge. During the third quarter of fiscal 2018, the Company further adjusted its assumptions and lowered the estimate of the sublease income rate and extended the time period to obtain a sub-tenant. As a result, the Company recorded an additional charge of $1.6 million. During the third quarter of fiscal 2019, the Company further updated its assumption regarding its ability to sublet the first floor and recorded an additional lease obligation charge of $1.4 million. These estimates may vary from the actual sublease agreements executed, if any, resulting in an adjustment to the charge. The Company has vacated other portions of the building but not the entire facility, and at this time does not meet the cease-use date criteria to record additional restructuring charges.